Head-to-head evidence
Ambrisentan vs F230
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Endothelin A receptor · full Hypertension pipeline
Ambrisentan · Letairis
Marketed by Gilead Sciences
NCT00091598 · Phase 3 · completed
This was a randomized, double-blinded trial with 372 patients and a validated functional endpoint for pulmonary hypertension. Both doses produced a statistically significant, placebo-corrected improvement in six-minute walk distance (+31 m at 5 mg, p=0.008; +51 m at 10 mg, p<0.001).
Next expected readout: February 2028 · NCT06987097 (registry estimate)
F230
Developed by Gyre Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ambrisentan's landscape · F230's landscape